

PreComb announces the formation of the Strategic Advisory Board

Wädenswil, Switzerland, September 21st, 2018 - PreComb, the leader in micro-tumor-based drug discovery, today announced the formation of its new advisory board, a strategic committee of trusted advisors.

"The search for experienced Advisory Board members to support the development of PreComb has been a thoughtful exercise" said Jens M. Kelm, CEO of PreComb Therapeutics. "We've been very fortunate to attract highly networked advisors with extensive practical experiences in Biotech industry, preclinical and clinical cancer research. We are looking forward to work with our advisors to quickly implement our ideas and leverage their expertise to develop novel anti-cancer combination therapies.

Appointments of the Strategic advisory board include:

Dominik Escher, PhD Founding partner of Puros Bioventures and former founder and CEO of ESBATech AG

Prof. Heinz Zwierzina, MD Head of the Early Clinical Trial Unit within the Department for Haematology and Oncology at the University Hospital, Innsbruck

Prof. Laura Suter-Dick, PhD Professor for Molecular Toxicology at the University of Applied Sciences Northwestern Switzerland (FHNW)

About PreComb Therapeutics

PreComb Therapeutics AG is a swiss-based biotechnology company focusing on the development of novel combination therapies, primarily for the use in oncology and immuno-oncology. PreComb is developing a phenotypical drug development platform using 3D microtissue culture to enable high-throughput combinatorial drug screening. The platform shall deliver more efficient cancer therapies to substantially improve long-term prognosis and quality-of-life for patients.

For more Information about PreComb Therapeutics, please visit <https://www.precomb.com> or follow us on [LinkedIn](#).

Media contact

PreComb Therapeutics AG
Dr. Peter Steiner
info@precomb.com